The mission of this ACISR is to advance therapeutics for schizophrenia in order to reduce suffering and improve quality of life of persons afflicted with this group of diseases. We plan to advance therapeutic knowledge, and the application of this knowledge, by establishing core infrastructure functions that support a series of investigators in integrated research and dissemination activities. The research will advance knowledge on efficacy and effectiveness through clinical trials; effectiveness and the study of clinical practice through access to data from source categories (i.e., ACISR clinical trials; ACISR associated state-wide databases; industry data sets); and services research through integration with our Department's Center for Mental Health Services Research (CMHS) and the Mental Illness Research, Education, and Clinical Center (MIRECC). Dissemination of knowledge will be conducted in conjunction with the Schizophrenia Patient Outcomes Research Team (PORT) and the Research on Dissemination Core of the NIMH Center for Research on Services for Severe Mental Illness (SMI Center) and with Maryland's Mental Hygiene Administrations Services Training Center/Evidence-based Practices Center. The ACISR will support this work by: 1) developing and maintaining access to a variety of clinical sites for the conduct of clinical trials; 2) developing and maintaining databases reflecting general practice in Maryland with the ability to cross-reference findings across categorically discrete datasets; 3) fostering multi-disciplinary research in order to translate basic and clinical neuroscience knowledge into therapeutic research; 4) fostering multi-disciplinary research and planning in order to disseminate effectively therapeutic knowledge; 5) developing new technologies, methods, and designs for clinical studies; 6) assuring assessment, data management, statistical, and subject recruitment support for investigators; 7) developing innovative ethics methods; and 8) providing training for post-graduate trainees in clinical research.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-CRB-B (01))
Program Officer
Hsiao, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Schools of Medicine
United States
Zip Code
Keller, William R; Fischer, Bernard A; McMahon, Robert et al. (2014) Community adherence to schizophrenia treatment and safety monitoring guidelines. J Nerv Ment Dis 202:6-12
Allen, Daniel N; Strauss, Gregory P; Barchard, Kimberly A et al. (2013) Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia. Schizophr Res 146:132-7
Strauss, Gregory P; Horan, William P; Kirkpatrick, Brian et al. (2013) Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res 47:783-90
Weiner, Elaine; Ball, M Patricia; Buchholz, Alison S et al. (2012) Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry 73:95-102
Strauss, Gregory P; Allen, Daniel N; Miski, Pinar et al. (2012) Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. Schizophr Res 135:134-8
Boggs, Douglas L; Kelly, Deanna L; McMahon, Robert P et al. (2012) Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 134:207-10
Wehring, Heidi J; Liu, Fang; McMahon, Robert P et al. (2012) Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr Res 138:285-9
Rummel-Kluge, Christine; Komossa, Katja; Schwarz, Sandra et al. (2012) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38:167-77
Kasanova, Zuzana; Waltz, James A; Strauss, Gregory P et al. (2011) Optimizing vs. matching: response strategy in a probabilistic learning task is associated with negative symptoms of schizophrenia. Schizophr Res 127:215-22
Ball, M Patricia; Warren, Kimberly R; Feldman, Stephanie et al. (2011) Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 5:17-25

Showing the most recent 10 out of 61 publications